Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Jonathan Alter, journalist and author, discusses Trump's threats to take back the Panama Canal, unraveling foreign policy work done by Jimmy Carter in 1978.
Curious as to what your latest streaming bundle will look like? Find out what the future of media looks like from Ken Leon, Research Director, at CFRA. Watch!
Nathan Bomey, Reporter at Axios, discusses where Tesla stands, Musk's relationship with the incoming president and expectations for Tesla throughout 2025.
Senior Writer at Fast Company, Elizabeth Segran, discusses how Sephora has become the dominant beauty retailer and why brands want to sell there. Watch!
Matt Calkins, CEO of Appian, breaks down the recent bipartisan report on AI safety and shares thoughts on future privacy enhancements needed in the space.
